Pantothenic Acid

Pantothenic acid acts exclusively as a precursor to two active cofactors: Coenzyme A and the 4'-phosphopantetheine prosthetic group of acyl carrier protein (ACP). The vitamin itself has no catalytic function — its biological role is to be converted to CoA, and CoA then does everything. Dissecting the mechanism requires walking the biosynthetic pathway and mapping where CoA operates downstream.

Biosynthesis of CoA begins with pantothenate uptake via the sodium-dependent multivitamin transporter SMVT (SLC5A6), which co-imports sodium and also handles biotin and alpha-lipoic acid. Once intracellular, pantothenate undergoes five enzymatic steps. Step one is phosphorylation by pantothenate kinase (PANK), using ATP, to yield 4'-phosphopantothenate. Humans express four PANK isoforms: PANK1α and PANK1β (ubiquitous, cytosolic/mitochondrial splice variants), PANK2 (heart and brain enriched, mitochondrial matrix), PANK3 (liver enriched), and PANK4 (catalytically inactive pseudokinase regulating the others). PANK is allosterically inhibited by CoA and its acyl-thioesters, providing end-product feedback; this is the rate-limiting step. Loss-of-function PANK2 mutations cause PKANbecause mitochondrial CoA synthesis collapses in high-demand tissues (striatum, retina). Step two is condensation with cysteine by PPCS (phosphopantothenoylcysteine synthetase) to yield 4'-phosphopantothenoylcysteine. Step three is decarboxylation by PPCDC (phosphopantothenoylcysteine decarboxylase), producing 4'-phosphopantetheine. Step four is adenylation by PPAT (phosphopantetheine adenylyltransferase) to dephospho-CoA. Step five is a final phosphorylation by DPCK (dephospho-CoA kinase) to yield CoA. In humans, the final two steps are catalyzed by a single bifunctional enzyme, CoA synthase (CoASY); mutations in CoASY cause CoPAN (PMID 24183309), the sister syndrome to PKAN.

CoA is a complex molecule: a β-mercaptoethylamine thiol tip, connected through pantothenate and a pyrophosphate bridge to a 3'-phosphoadenosine. The business end is the terminal thiol (-SH), which forms high-energy thioester bonds with carboxylic acids. These thioesters (acyl-CoAs) are thermodynamically activated substrates — the free energy of thioester hydrolysis is roughly -31 kJ/mol, comparable to ATP's phosphoanhydride bond energy — which is why CoA activation is the universal entry point for substrate-level carboxyl group chemistry.

The 4'-phosphopantetheine prosthetic group, the C-terminal portion of CoA minus the adenine nucleotide, is covalently attached to acyl carrier protein (ACP) through a phosphodiester linkage to a conserved serine residue, catalyzed by phosphopantetheinyl transferases (PPTases such as AASDHPPT in humans). ACP exists as a standalone protein in bacterial type II fatty acid synthesis but is incorporated as an integrated domain of the megasynthase in eukaryotic type I fatty acid synthase (FAS) and polyketide synthases. The 4'-phosphopantetheine arm functions as a ~20-angstrom flexible tether that swings the growing fatty acyl chain between catalytic domains during each elongation cycle. Non-ribosomal peptide synthetases (NRPSs) use the analogous peptidyl carrier protein (PCP) domain for the same purpose during microbial peptide natural product synthesis.

Downstream CoA chemistry can be categorized into several buckets. (1) Central carbon metabolism: pyruvate dehydrogenase (PDH) uses CoA and thiamine diphosphate to convert pyruvate to acetyl-CoA, linking glycolysis to the TCA cycle; α-ketoglutarate dehydrogenase uses CoA and TPP to convert αKG to succinyl-CoA; the branched-chain α-keto acid dehydrogenase (BCKDH) processes leucine, isoleucine, and valine catabolism into branched acyl-CoAs. All three of these dehydrogenases also require riboflavin (FAD) and niacin (NAD+) for their multi-cofactor active sites — a tight interdependence of the B-complex. (2) β-oxidation: long-chain fatty acyl-CoAs are transported into mitochondria via carnitine shuttles and processed by acyl-CoA dehydrogenases (VLCAD, LCAD, MCAD, SCAD — each using FAD), enoyl-CoA hydratases, hydroxyacyl-CoA dehydrogenases (using NAD+), and thiolases (releasing acetyl-CoA). Every round of β-oxidation requires two CoA molecules. (3) Ketogenesis and cholesterol synthesis: HMG-CoA synthase condenses acetyl-CoA with acetoacetyl-CoA to yield HMG-CoA, the substrate for both HMG-CoA lyase (ketogenesis) and HMG-CoA reductase (cholesterol synthesis, statin target). (4) Lipogenesis: ACC converts acetyl-CoA to malonyl-CoA using biotin; FAS iteratively condenses malonyl-ACP onto the growing fatty acid chain on its 4'-phosphopantetheine arm. (5) Amino acid metabolism: propionyl-CoA carboxylase (biotin enzyme) converts propionyl-CoA from odd-chain fatty acids and BCAA catabolism to D-methylmalonyl-CoA, ultimately feeding succinyl-CoA via the vitamin B12-dependent methylmalonyl-CoA mutase. (6) Heme synthesis: δ-aminolevulinic acid synthase condenses succinyl-CoA with glycine using vitamin B6 PLP to initiate heme biosynthesis. (7) Histone and non-histone acetylation: GCN5, p300/CBP, and other histone acetyltransferases (HATs) use acetyl-CoA as the acetyl donor to write the histone acetylation code regulating gene expression; hundreds of non-histone proteins are similarly regulated. (8) Protein acylation: palmitoylation, myristoylation, and other lipid modifications anchor signaling proteins (Ras, Src kinases, SNAP25) to membranes using acyl-CoAs. (9) Neurotransmitter synthesis: choline acetyltransferase (ChAT) uses acetyl-CoA to synthesize acetylcholine in cholinergic neurons — choline availability matters here alongside pantothenate.

The thioester bond between CoA and acyl groups is the central engine. It is cleaved by hydrolases (acyl-CoA thioesterases, ACOTs) to regenerate free CoA, transferred to acceptor molecules by acyl transferases (for example, carnitine palmitoyltransferase moving the palmitoyl group from CoA to carnitine for mitochondrial import), or the acyl group is oxidized/reduced/modified while attached. Tissue CoA pools are dynamic; hepatocytes contain the highest concentrations (200–400 μM), with about 80–90% existing as acyl-CoA species at any moment. CoA itself is compartmentalized: separate cytosolic and mitochondrial pools exist with limited direct exchange (acyl groups cross compartments via carnitine shuttles or as free acids to be re-esterified).

Pantethine's bioactivity deserves a separate note. Pantethine is pantetheine-disulfide; on ingestion, pantethine is reduced to two pantetheine molecules by intracellular disulfide reductases, then phosphorylated by pantothenate kinase (same PANK that handles free pantothenate) — but because pantethine bypasses the earliest committed step and enters later in the pathway, it can raise intracellular CoA more efficiently than equimolar pantothenate. In vitro, pantethine and its CoA-elevating effects inhibit lipogenesis at the level of acetyl-CoA carboxylase feedback, modestly inhibit cholesterol synthesis at HMG-CoA reductase, and improve fatty acid oxidation. These combined mechanisms are the leading hypothesis for pantethine's modest lipid-lowering effect in clinical trials.

Dexpanthenol topical action differs from systemic B5. On skin and mucosal surfaces, dexpanthenol is rapidly oxidized to pantothenate, which is taken up by keratinocytes and fibroblasts and converted to CoA locally. But dexpanthenol also exerts direct humectant effects (hygroscopic molecule drawing water into the stratum corneum), modulates pro-inflammatory cytokines (down-regulates IL-1 and TNF-α in keratinocyte cultures), stimulates fibroblast proliferation and collagen synthesis, and improves epidermal barrier function (increases expression of filaggrin and loricrin). These are topical effects that do not translate to systemic pantothenate supplementation for skin benefit.

Pantothenic acid is the water-soluble B-complex vitamin — officially vitamin B5 — that every aerobic cell on the planet converts into Coenzyme A (CoA) and the 4'-phosphopantetheine prosthetic arm of acyl carrier protein (ACP). The name comes from the Greek "pantothen," meaning "from everywhere," a nod to its ubiquity in plant and animal foods and the near-impossibility of developing deficiency on a varied diet. Roger Williams isolated and named it at Oregon State in 1933 while hunting the yeast growth factor responsible for pellagra-adjacent syndromes; Fritz Lipmann's 1953 Nobel laureate work on Coenzyme A finally explained why this pale-yellow acid sat at the center of intermediary metabolism. Essentially every reaction that makes, breaks, or transfers a two-carbon acyl group — from acetyl-CoA feeding the TCA cycle to succinyl-CoA stoking heme synthesis to acetyl-CoA carboxylase (ACC, a biotin enzyme) committing carbons to fatty acid synthesis — requires a pantothenate-derived thiol handle. Without B5, the central metabolic hub simply does not spin.

Structurally pantothenic acid is a conjugate of D-pantoic acid and β-alanine linked through an amide bond. Humans cannot synthesize it and must obtain it from diet; the RDA is a modest 5 mg/day for adults, and the Institute of Medicine has not set a tolerable upper limit because toxicity is exceedingly rare at intakes up to several grams per day. Whole grains, eggs, organ meats, legumes, avocados, mushrooms, sweet potato, sunflower seeds, broccoli, and fermented dairy all provide generous amounts; food processing and alkaline cooking water destroy a portion, and prolonged frozen storage incrementally degrades it. Intestinal absorption occurs via the sodium-dependent multivitamin transporter SMVT (gene SLC5A6), the same carrier that transports biotin and alpha-lipoic acid — a shared logistics pipeline that creates the theoretical concern that megadose biotin might competitively inhibit pantothenate uptake, though no clinically meaningful case of this has been documented. Once absorbed, pantothenate is not stored in any meaningful depot; free pantothenate circulates in plasma at low micromolar concentrations, while tissues hold the vitamin almost entirely as CoA and its acyl-thioester derivatives (acetyl-CoA, malonyl-CoA, succinyl-CoA, palmitoyl-CoA, HMG-CoA, acyl-CoA intermediates).

Inside cells pantothenate is funneled through a five-step biosynthesis to CoA. Pantothenate kinase (PANK, encoded by PANK1-4) performs the committed, rate-limiting phosphorylation to 4'-phosphopantothenate. PPCS and PPCDC ligate cysteine and decarboxylate to yield 4'-phosphopantetheine. PPAT adds AMP, and DPCK phosphorylates to finish the molecule. Loss-of-function mutations in PANK2 cause pantothenate kinase-associated neurodegeneration (PKAN), historically called Hallervorden-Spatz disease, a devastating autosomal recessive disorder of childhood-onset dystonia, pigmentary retinopathy, and iron deposition in the globus pallidus producing the pathognomonic "eye-of-the-tiger" MRI sign. PMID 11479594 (Zhou, Nature Genetics 2001) cloned the PANK2 gene; mutations in CoASY — the bifunctional enzyme that completes CoA biosynthesis — cause a closely related syndrome called CoPAN (PMID 24183309). Both diseases sit within the larger spectrum called neurodegeneration with brain iron accumulation (NBIA), and both illustrate that when CoA biosynthesis falters even locally, neurons suffer catastrophically. Pantethine and 4'-phosphopantetheine rescue experiments in model systems have motivated ongoing trials of fosmetpantotenate and CoA-replacement strategies (fosmetpantotenate's key FORT trial in 2019 unfortunately did not meet its primary endpoint), but the biology robustly establishes why B5 sits at the foundation of cellular metabolism.

The metabolic reach of CoA is almost impossible to overstate. Acetyl-CoA is the universal two-carbon currency produced from pyruvate (by the thiamine-dependent pyruvate dehydrogenase complex), from β-oxidation of fatty acids (by acyl-CoA dehydrogenases using FAD from riboflavin), from ketone body catabolism, and from ketogenic amino acid degradation. Acetyl-CoA then feeds the TCA cycle via citrate synthase, donates acetyl groups to histone acetyltransferases writing the histone acetylation code that regulates gene expression, acetylates hundreds of non-histone proteins regulating everything from metabolism to autophagy, is the starting substrate for de novo cholesterol synthesis (via HMG-CoA reductase, the statin target), is the precursor for ketogenesis during fasting, and is the carbon source for fatty acid biosynthesis (through malonyl-CoA generated by ACC, the biotin carboxylase). Succinyl-CoA feeds heme synthesis (via δ-ALA synthase) and the GABA shunt. Acyl-CoAs drive protein acylation (palmitoylation, myristoylation) anchoring signaling proteins to membranes. The 4'-phosphopantetheine arm, covalently tethered to serine residues on acyl carrier protein (ACP) in fatty acid synthase and on peptidyl carrier protein domains in non-ribosomal peptide synthetases, is the swinging boom that shuttles growing acyl and peptidyl intermediates between catalytic domains — a physical shuttle that depends on B5 being present in sufficient quantity. Every cell, every day.

Pantothenic acid is commercially available in three main forms. Calcium D-pantothenate is the most common, a stable white crystalline salt used in food fortification and most multivitamins. D-pantothenic acid free acid is hygroscopic and less convenient. Dexpanthenol (D-panthenol) is the alcohol analog that is rapidly oxidized to pantothenate in vivo; it is the workhorse of topical dermatology (Bepanthen cream, Panthenol foam, nasal sprays, eye ointments) and provides well-documented moisturizing, barrier-restoring, and wound-healing effects on skin, mucous membranes, and hair shaft. Pantethine is pantetheine-disulfide, the dimeric form of 4'-phosphopantetheine's precursor; it bypasses PANK regulation and can raise intracellular CoA more efficiently than pantothenate at equimolar dose. A body of older Italian and Japanese literature ( Rumberger meta-analysis EFSA scientific opinion context) documented 10–15% reductions in LDL and triglycerides with 900 mg/day pantethine — modest effects by modern standards but real and sustained in small trials. A 2014 randomized controlled trial by Rumberger and colleaguesof 120 low-to-moderate cardiovascular risk subjects on a TLC diet showed pantethine 600 mg/day for 16 weeks produced a 4% LDL and 11% triglyceride reduction vs. placebo, reaching statistical significance. Pantethine is not a statin and should not be framed as one, but it is an interesting adjunct with a tolerability profile dramatically better than niacin.

Deficiency is the exception, not the rule. Controlled depletion studies in conscientious objectors during the 1950s, and in POWs during WWII, produced the classic "burning feet syndrome" (dysesthesias in the plantar surfaces), mood changes, fatigue, and eventually peripheral neuropathy — but only after weeks of semi-synthetic diets deliberately free of B5, sometimes combined with the pantothenate antagonist ω-methyl-pantothenate. No endemic B5 deficiency exists in modern populations. Subclinical insufficiency may contribute to symptomatology in severe malabsorption syndromes (Crohn's, short bowel, celiac), alcohol use disorder (impaired absorption and increased turnover), and rare inherited pantothenate kinase and CoASY mutations described above. The supplement industry's "adrenal fatigue" narrative — claiming pantothenic acid supports stressed adrenals because steroidogenesis uses CoA — is reductionist and unsupported by controlled trials; adrenal steroid hormone production is CoA-dependent but is not rate-limited by pantothenate at normal dietary intakes. Stress physiology matters, but B5 megadosing is not its solution.

Two niche clinical literatures are worth honest framing. First, acne: Leung's 1995 open-label trial ( conceptual echo; original J Orthomolecular Med) of 10,000 mg/day calcium pantothenate in 100 acne patients reported dramatic lesion reduction within 4–8 weeks, a finding replicated by a small 2012 placebo-controlled study (Yang et al., J Cosmetic Dermatol) in 48 subjects using a pantothenic-acid-based supplement showing roughly 50% lesion reduction at 12 weeks. The mechanistic story — that CoA limitation impairs sebum fatty acid elongation and drives follicular hyperkeratinization — is chemistry-plausible but not rigorously proven, and the enormous doses required (10 g/day) raise questions about which bioactive is actually responsible. Second, dermatology: dexpanthenol 5% cream is one of the best-studied OTC wound-healing and barrier-restoring agents; Proksch 2017 complete reviewsynthesized 57 studies showing reliable benefit for atopic dermatitis, irritant dermatitis, diaper rash, and post-procedure skin recovery. These are real topical effects and do not imply systemic B5 deficiency.

BodyHackGuide's take: pantothenic acid is the quiet foundation of nearly every metabolic pathway you improve with other nutrients. You cannot out-train, out-supplement, or out-biohack a CoA deficit, but given how abundant B5 is in food, you almost certainly do not have one. A B-complex providing 10–100 mg/day is reasonable insurance and carries essentially zero risk; pantethine 600–900 mg/day is a legitimate lipid-modifying option with a decent evidence base for the patient who does not tolerate or qualify for statins; dexpanthenol topical is a first-line dermatology tool. Mega-dose calcium pantothenate for acne sits in the "interesting but unproven" bucket — it is low-risk but should not supplant tretinoin, benzoyl peroxide, or isotretinoin for moderate-to-severe disease. Pantothenic acid belongs alongside thiamine, riboflavin, niacin, vitamin B6, biotin, folate, and vitamin B12 as the chassis of the B-complex — not because any of them are glamorous, but because cellular energetics collapse without them.

IUPAC Name

Not yet available

CAS Number

Not yet available

Molecular Formula

Not yet available

Molecular Mass

Not yet available

Unlock Dosing Protocols

Free account gets you:

• View beginner, intermediate & advanced protocols
• See weight-based dosing calculations
• Access cycle length & frequency data

2,800+ researchers already in

Unlock Research Data

Free account gets you:

• Browse PubMed study summaries
• See clinical trial phases & results
• Access mechanism of action details

2,800+ researchers already in

Get Pantothenic Acid Price Drop Alerts

Set a target price and we'll notify you when any vendor drops below it.

Related Compounds

Data Completeness

Research Credibility